News from ATS 2018: Philips, ResMed back combined therapy

 - 
Tuesday, May 22, 2018

SAN DIEGO – Royal Philips announced new data at ATS 2018 that suggests combining home oxygen therapy with home non-invasive ventilation as treatment for chronically hypercapnic COPD patients is more effective and less expensive than HOT alone.

Comparing the accumulated costs of devices, doctor visits, medication and hospitalizations using a U.S. economic model, HOT-HMV exhibited an average annual cost savings of $3,927 per patient.

Results of the five-year, multi-center study were announced at ATS 2017 and published in the Journal of American Medical Association, but the potential health economic impact was previously unknown. The original trial data were used to develop an economic model from the U.S. payer perspective.

This analysis indicated the base-case incremental cost per quality adjusted life year (QALY) gained was negative $50,856, suggesting HOT-HMV as a dominant strategy to both save costs and improve quality of life.

ResMed announced the results of two studies at ATS 2018 that demonstrate the cost effectiveness of combining home oxygen therapy and home non-invasive ventilation therapy for patients with persistent hypercapnia following a life-threatening exacerbation of COPD.

The ResMed-backed Home Oxygen Therapy – Home Mechanical Ventilation (HOT-HMV) health economic studies build on earlier data demonstrating the clinical and cost effectiveness of combined therapy.

A U.K. study found that HOT-HMV treatment reduced exacerbation frequency and 28-day hospital readmissions. A U.S. analysis based on the U.K. study found a 58.3% reduction in 30-day readmissions for HOT-HMV patients and the ability to save patients money while improving their quality of life.